This was the stock's second consecutive day of gains.

RBC Capital Markets adjusted its price target for Regeneron Pharmaceuticals (NASDAQ:REGN), reducing it to $1,045 from the previous target of $1,059. Despite the decrease, the firm maintained its ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over ...

The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

(REGN) on Tuesday reported fourth-quarter net income of $917.7 million. The Tarrytown, New York-based company said it ...

Shares of Regeneron Pharmaceuticals Inc. REGN slipped 1.48% to $672.98 Friday, on what proved to be an all-around grim ...